The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Hepatitis B virus receptors and molecular drug targets
Open accessAbstract
Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Virus-induced diseases include cirrhosis, liver failure and hepatocellular carcinoma. Current therapeutic strategies may at best control infection without reaching cure. Complementary antiviral strategies aimed at viral cure are therefore urgently needed. HBV entry is the first step of the infection cycle, which leads to the formation of cccDNA and the establishment of chronic infection. Viral entry may thus represent an attractive target for antiviral therapy. This review summarizes the molecular virology and cell biology of HBV entry, including the discovery and development of new HBV entry inhibitors, and discusses their potential in future treatment of HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of NTCP by Myrcludex B (bulevirtide) may reduce intrahepatic BA levels.
“Inhibition of NTCP by Myrcludex B (bulevirtide), a small peptide inhibitor originally designed to prevent hepatitis B virus uptake via NTCP, may also reduce intrahepatic BA levels.203”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El‐Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,384
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, X., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,178
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Immunology of hepatitis B virus and hepatitis C virus infection
Rehermann, B., & Nascimbeni, M. (2005) · Nature reviews. Immunology · doi:10.1038/nri1573 · Cited by 1,618
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Seyec, J. L., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., TREPO, C. G., & Guguen‐Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,288
Sells, M. A., Chen, M. L., & Acs, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.4.1005 · Cited by 1,121
Liver Transplantation in European Patients with the Hepatitis B Surface Antigen
Samuel, D., Müller, R., Alexander, G., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312163292503 · Cited by 1,047
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 932
Ni, Y., Lempp, F. A., Mehrle, S., Nkongolo, S., Kaufman, C., Fälth, M., Stindt, J., Königer, C., Nassal, M., Kubitz, R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.12.024 · Cited by 807
Ladner, S. K., Otto, M. J., Barker, C. S., Zaifert, K., Wang, G. H., Guo, J., Seeger, C., & King, R. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1715 · Cited by 644
Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., Petersen, J., Raimondo, G., Dandri, M., & Levrero, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58847 · Cited by 594
Filmus, J., Capurro, M., & Rast, J. P. (2008) · Genome biology · doi:10.1186/gb-2008-9-5-224 · Cited by 555
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
Wedemeyer, H. H., Yurdaydın, C., Dalekos, G. Ν., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0912696 · Cited by 489
Hagenbuch, B., & Meier, P. J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117091 · Cited by 460
Schulze, A., Gripon, P., & Urban, S. (2007) · Hepatology · doi:10.1002/hep.21896 · Cited by 445
Petersen, J., Dandri, M., Mier, W., Lütgehetmann, M., Volz, T., von Weizsäcker, F., Haberkorn, U., Fischer, L., Pollok, J., Erbes, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1389 · Cited by 396
Gripon, P., Cannie, I., & Urban, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1613-1622.2005 · Cited by 347
Volz, T., Allweiss, L., ́Barek, M. M., Warlich, M., Lohse, A. W., Pollok, J. M., Alexandrov, A., Urban, S., Petersen, J., Lütgehetmann, M., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.008 · Cited by 331
Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban, S., Bartenschlager, R., Kubitz, R., & Zoulim, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.030 · Cited by 315
Viral and cellular determinants involved in hepadnaviral entry
Glebe, D. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i1.22 · Cited by 285
Watashi, K., Sluder, A. E., Daito, T., Matsunaga, S., Ryo, A., Nagamori, S., Iwamoto, M., Nakajima, S., Tsukuda, S., Borroto–Esoda, K., et al. (2013) · Hepatology · doi:10.1002/hep.26982 · Cited by 271
Yan, H., Peng, X., Liu, Y., Xu, G., He, W., Ren, B., Jing, Z., Sui, J., & Li, W. (2014) · Journal of Virology · doi:10.1128/jvi.03478-13 · Cited by 264
Gripon, P., Diot, C., Thézé, N., Fourel, I., Loréal, O., Bréchot, C., & Guguen‐Guillouzo, C. (1988) · Journal of Virology · doi:10.1128/jvi.62.11.4136-4143.1988 · Cited by 260
Nkongolo, S., Ni, Y., Lempp, F. A., Kaufman, C., Lindner, T., Esser‐Nobis, K., Lohmann, V., Mier, W., Mehrle, S., & Urban, S. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.022 · Cited by 257
Zeisel, M. B., Lucifora, J., Mason, W. S., Sureau, C., Beck, J., Levrero, M., Kann, M., Knolle, P. A., Benkirane, M., Durantel, D., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308943 · Cited by 256
Self-citationHepatitis B Virus Infection of Tupaia Hepatocytes In Vitro And In Vivo
Walter, E., Keist, R., Niederöst, B. P., Pult, I., & Blum, H. E. (1996) · Hepatology · doi:10.1002/hep.510240101 · Cited by 239
Broadly neutralizing antibodies abrogate established hepatitis C virus infection
de Jong, Y. P., Dorner, M., Mommersteeg, M. C., Xiao, J., Balazs, A. B., Robbins, J. B., Winer, B. Y., Gerges, S., Vega, K., Labitt, R. N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009512 · Cited by 236
Sureau, C., & Salisse, J. (2012) · Hepatology · doi:10.1002/hep.26125 · Cited by 218
Self-citationVerrier, E. R., Colpitts, C. C., Bach, C., Heydmann, L., Weiss, A., Renaud, M., Durand, S., Habersetzer, F., Durantel, D., Abou-Jaoudé, G., et al. (2015) · Hepatology · doi:10.1002/hep.28013 · Cited by 210
Self-citationRole of glycosaminoglycans for binding and infection of hepatitis B virus
Leistner, C. M., Grün, S., & Glebe, D. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.01023.x · Cited by 205
Yan, H., Peng, X., He, W., Zhong, G., Qi, Y., Ren, B., Gao, Z., Jing, Z., Song, M. L., Xu, G., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03540-12 · Cited by 202
The solute carrier family 10 (SLC10): Beyond bile acid transport
da Silva, T. C., Polli, J. E., & Swaan, P. W. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.004 · Cited by 194
Huang, H., Chen, C., Chang, W.-C., Tao, M., & Huang, C. (2012) · Journal of Virology · doi:10.1128/jvi.00873-12 · Cited by 182
Baumert, T. F., Rogers, S., Hasegawa, K., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119037 · Cited by 180
Self-citationPre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus
Glebe, D., Aliakbari, M., Krass, P., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9511-9521.2003 · Cited by 176
Liu, F., Campagna, M., Qi, Y., Zhao, X., Guo, F., Xu, C., Li, S., Li, W., Block, T. M., Chang, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003613 · Cited by 171
Fresh Approaches to Anti-Infective Therapies
Nathan, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003081 · Cited by 167
Characterization of a hepatitis B and hepatitis delta virus receptor binding site†
Engelke, M., Mills, K. E., Seitz, S., et al. (2006) · Hepatology · doi:10.1002/hep.21112 · Cited by 156
Mailly, L., Xiao, F., Lupberger, J., Wilson, G. K., Aubert, P., Duong, F. H. T., Calabrese, D., Leboeuf, C., Fofana, I., Thumann, C., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3179 · Cited by 150
Self-citation(−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes
Huang, H., Tao, M., Hung, T., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.09.009 · Cited by 150
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
Li, F., Shi, W., Capurro, M., & Filmus, J. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201008087 · Cited by 150
The role of glypicans in Hedgehog signaling
Filmus, J., & Capurro, M. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.12.007 · Cited by 140
Hepatitis B Virus Requires Intact Caveolin-1 Function for Productive Infection in HepaRG Cells
Macovei, A., Radulescu, C., Lazar, C., Petrescu, S. M., Durantel, D., Dwek, R. A., Zitzmann, N., & Nichita, N. B. (2009) · Journal of Virology · doi:10.1128/jvi.01207-09 · Cited by 127
Zhang, T., Yuan, Q., Zhao, J.-H., Zhang, Y., Yuan, L., Lan, Y., Lo, Y.-C., Sun, C., Wu, C., Zhang, J., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308964 · Cited by 126
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes
Lucifora, J., Esser, K., & Protzer, U. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.12.008 · Cited by 118
Hu, H., Liu, J., Lin, Y.-L., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310686 · Cited by 114
Dong, Z., Ekins, S., & Polli, J. E. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300453k · Cited by 104
Kaneko, M., Watashi, K., Kamisuki, S., Matsunaga, H., Iwamoto, M., Kawai, F., Ohashi, H., Tsukuda, S., Shimura, S., Suzuki, R., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01855-15 · Cited by 104
Self-citationThe p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B
Peng, L., Zhao, Q., Li, Q., Li, M., Li, C., Xu, T., Jing, X., Zhu, X., Wang, Y., Li, F., et al. (2014) · Hepatology · doi:10.1002/hep.27608 · Cited by 103
A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses
Krepstakies, M., Lucifora, J., Nagel, C., Zeisel, M. B., Holstermann, B., Hohenberg, H., Kowalski, I., Gutsmann, T., Baumert, T. F., Brandenburg, K., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis273 · Cited by 92
Self-citationMicrobial Subversion of Heparan Sulfate Proteoglycans
Chen, Y., Götte, M., Liu, J., & Park, P. W. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)14017-9 · Cited by 84
Eren, R., Ilan, E., Nussbaum, O., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.9632 · Cited by 83
Galun, E., Eren, R., Safadi, R., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.31867 · Cited by 81
Lempp, F. A., Mutz, P., Lipps, C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.030 · Cited by 80
Blanchet, M., Sureau, C., & Labonté, P. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.017 · Cited by 78
Self-citationProteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors
Longarela, O. L., Schmidt, T. T., Schöneweis, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058340 · Cited by 77
Hong, H. J., Ryu, C. J., Hur, H., et al. (2003) · Virology · doi:10.1016/j.virol.2003.09.014 · Cited by 75
Ko, C., Park, W.-J., Park, S., Kim, S., Windisch, M. P., & Ryu, W. (2014) · Antiviral Therapy · doi:10.3851/imp2965 · Cited by 71
Petcu, D. J., Aldrich, C. E., Coates, L. C., Taylor, J. M., & Mason, W. S. (1988) · Virology · doi:10.1016/0042-6822(88)90099-2 · Cited by 70
Entry of hepatitis B and C viruses — recent progress and future impact
Baumert, T. F., Meredith, L. W., Ni, Y., et al. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.12.002 · Cited by 59
Self-citationChronic hepatitis D at a standstill: where do we go from here?
Ciancio, A., & Rizzetto, M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.164 · Cited by 49
Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections
Colpitts, C. C., Verrier, E. R., & Baumert, T. F. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00039 · Cited by 47
Self-citationHost-targeting agents for treatment of hepatitis B virus infection
Baumert, T. F., Verrier, E. R., Nassal, M., Chung, R. T., & Zeisel, M. B. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.07.009 · Cited by 41
Self-citationExperimental models and therapeutic approaches for HBV
Dandri, M., Lütgehetmann, M., & Petersen, J. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0335-7 · Cited by 37
New challenges in viral hepatitis
Thomas, D. L., & Zoulim, F. (2012) · Gut · doi:10.1136/gutjnl-2012-302122 · Cited by 32
a proof-of-concept Phase 2a clinical trial with Hbv/hdv entry inhibitor Myrcludex B : lb-20
Bogomolov, P., Воронкова, Н. В., Allweiss, L., et al. (2014) · Hepatology · Cited by 29
Petcu, D. J., Aldrich, C. E., COATES, L., et al. (1988) · Virology · doi:10.1016/s0042-6822(88)90099-2 · Cited by 27
Urban, S. (2015) · Hepatology · doi:10.1002/hep.28308 · Cited by 11
Sureau, C. (2015) · Gut · doi:10.1136/gutjnl-2015-310978 · Cited by 7
Self-citationMailly, L., Xiao, F., Lupberger, J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30880-1 · Cited by 6
Flagged first, then by citations
Cited by
Sorted by citations
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Metadata
- Authors
- Verrier, E. R., Colpitts, C. C., Sureau, C., & Baumert, T. F.
- Affiliations
- Inserm (FR)
- Institut National de la Transfusion Sanguine (FR)
- Corresponding author
- Baumert, Thomas F.
- Venue
- Hepatology International
- Published
- 2016-03-15
- Volume
- 10
- Issue
- 4
- Pages
- 567-573
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- PMC
- PMC7613476
- OpenAlex
- W2298618978
- Cited by
- 25
- References
- 70
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2016: 3
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Hepatology International (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- univOAK (4 institutions : Université de Strasbourg, Université de Haute Alsace, INSA Strasbourg, Bibliothèque Nationale et Universitaire de Strasbourg) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatitis B virus, viral receptor, entry inhibitors, antiviral drug targets, chronic hepatitis B, covalently closed circular DNA, hepatocellular carcinoma, liver disease
- MeSH terms
- Antiviral Agents, Hepatitis B virus, Humans, Receptors, Virus, Virus Replication, Hepatitis B, Chronic, Virus Attachment, Virus Internalization, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
